

Enterprise One Pain Management Service

Executive Summary – 1 July 2023 to 30 June 2024



Patient profile

Enterprise One received 230 completed referral questionnaires in this period (all services, n = 22548)

Demographic information	Your service	All services
Sex (female)	57.0%	59.2%
Average age (years)	43.7	51.1
Interpreter required	1.3%	3.0%
Communication assistance required	3.5%	7.6%
Living in highest disadvantage area	12.9%	21.3%
Aboriginal and/or Torres Strait Islander	2.2%	6.1%

Clinical characteristics	Your service	All services
Average number of pain sites	4.4	4.4
Average number of comorbidities	1.9	2.7
% using opioids > 2 days/week	20.3	39.4
Average oMEDD (mg)	28.8	43.3
Average number of drug groups used	1.8	2.0
% outside normal BMI range	72.3	75.0
% experiencing pain >5 years	25.1	43.5
% unemployed due to pain	30.0	36.0

Services provided

	Your service	All services
Episodes of care started	297	18391
Waiting time* (median days)	48	60
Patients participating in education/orientation programs	0	4926
Patients assessed by multidisciplinary team	1	2032
No. of treatment pathways started	241	13091
Treatment pathway type (%)		
- Group program	41.1	24.6
- Individual	17.0	51.1
- Concurrent	41.9	16.0
- Other	0.0	8.2
Episodes of care ended	132	12184

* Days from referral received to episode start

Pain severity	5.7	6.2
Pain interference	6.5	6.9
	Mild / Moderate / Severe	
Depression	17.8	18.8
Anxiety	11.2	12.8
Stress	19.7	19.7
	Normal / Mild / Moderate / Severe / Extremely severe	
Pain catastrophising	26.0	28.3
	Mild / High / Severe	
Pain self-efficacy	22.1	20.8
	Minimal / Mild / Moderate / Severe impairment	

Collection of patient outcomes

A detailed summary of outcome collection rates at episode end and at post-episode follow-up can be found in the appendices of your report.

Benchmark & indicator summary

Benchmarks (BM)	BM target	Your service			All services		
		Patient outcomes included (n)	Positive outcomes* (%)	BM met?	Patient outcomes included (n)	Positive outcomes* (%)	Services met BM
Average pain <i>Patients with moderate or severe average pain at referral who have made a clinically significant improvement at episode end</i>	40%	79	21.5%	No	2995	27.9%	7/62
Pain interference <i>Patients with moderate or severe pain interference at referral who have made a clinically significant improvement at episode end</i>	70%	90	62.2%	No	3343	60.5%	12/64
Depression <i>Patients with moderate, severe or extremely severe depression at referral who have made a clinically significant improvement at episode end</i>	70%	60	46.7%	No	2268	54.9%	6/56
Anxiety <i>Patients with moderate, severe or extremely severe anxiety at referral who have made a clinically significant improvement at episode end</i>	50%	52	40.4%	No	2054	41.5%	9/53
Stress <i>Patients with moderate, severe or extremely severe stress at referral who have made a clinically significant improvement at episode end</i>	60%	48	45.8%	No	1838	57.8%	20/45
Pain catastrophising <i>Patients with high or severe pain catastrophising at referral who have made a clinically significant improvement at episode end</i>	70%	66	56.1%	No	2544	55.8%	9/58
Pain self-efficacy <i>Patients with impaired self-efficacy (moderate or severe) at referral who have made a clinically significant improvement at episode end</i>	60%	77	46.8%	No	2861	48.1%	13/60
Opioid use <i>Patients taking opioids at referral who report a reduction in their oMEDD[†] of at least 50% at episode end</i>	60% ^{††}	22	36.4%	No	1325	55.2%	17/42
Opioid use (high dose) <i>Patients reporting 40mg or more oMEDD[†] at referral who report a reduction of at least 50% at episode end</i>	60%	4	-	-	428	50.5%	2/13
Indicators							
Wait time – 3 months <i>Episodes starting within 3 months of the referral being received</i>	-	297	83.2%	-	18195	63.7%	-
Wait time – 8 weeks <i>Episodes starting within 8 weeks of the referral being received</i>	-	297	59.3%	-	18195	48.6%	-

* Positive outcomes describes the percentage of patients making a clinically significant improvement, or reducing oMEDD by 50% or having their episode start within 3 months/8 weeks where relevant

† oMEDD = oral morphine equivalent daily dose

†† The all-dose opioid use benchmark has been raised from 50% to 60% from the 2022 mid-year report onwards

- is shown for the benchmarks and indicators where less than 10 outcomes are included